<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03515798</url>
  </required_header>
  <id_info>
    <org_study_id>PELICAN-IPC 2015-016</org_study_id>
    <secondary_id>2016-001868-11</secondary_id>
    <nct_id>NCT03515798</nct_id>
  </id_info>
  <brief_title>Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer</brief_title>
  <acronym>PELICAN</acronym>
  <official_title>A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MSD France</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oncodistinct</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II multicentre randomized open-label study will assess the safety and efficacy of
      Pembrolizumab in combination with standard chemotherapy in inflammatory breast cancer.
      Pembrolizumab will be administered every 3 weeks during the neoadjuvant chemotherapy. Tissue
      and blood samples will be collected pre- and post-treatment for translational research.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inflammatory breast cancer (IBC) is a rare and highly aggressive subtype of locally advanced
      breast cancer representing approximately 5% of all breast cancers that requires immediate
      aggressive treatment. Significant progress has been made in recent years using a combination
      of treatments, including neoadjuvant chemotherapy, surgery and radiation therapy.

      Accumulating data indicate a prognostic and/or predictive impact for immune-response
      variables in BC. Recent data, suggest that PD-L1 is overexpressed in a significant number of
      BC, notably in IBC and may have significant prognostic or predictive value. Furthermore it
      may be targeted to restore or boost functional antitumor immunity. Pembrolizumab, a
      PD-1-directed monoclonal antibody is already registered and has an out-standing activity in
      advanced melanoma and NSCLC patients, with promising results in several other tumor types,
      including triple-negative BC, and a favorable profile of tolerance.

      Thus, potential benefits of pembrolizumab in combination with a conventional cytotoxic
      backbone may be considered as high in HER2-negative IBC.

      The aim of the study is to assess the pathological complete response rate following
      neoadjuvant EC-paclitaxel chemotherapy plus pembrolizumab and to assess if neoadjuvant
      chemotherapy with anthracycline-based induction in combination with pembrolizumab exposes IBC
      patients to significant toxicity. rates.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central evaluation of pathological complete response rate</measure>
    <time_frame>Following completion of neoadjuvant systemic treatment, an average of 24 weeks</time_frame>
    <description>absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of NAST (i.e., ypT0/is, ypN0 in the current AJCC staging system)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT) rates</measure>
    <time_frame>during 21 days following the first administration of pembrolizumab</time_frame>
    <description>incidence of DLT during the 21 days following the first administration of pembrolizumab in combination with EC, will be assessed separately in the first 3 patients of each stratum (HR+ and HR-). DLTs will be defined according to CTCAE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurrence of serious adverse events and adverse events starting grade 2 or grade 1 (run-in period)</measure>
    <time_frame>during 21 days following the first administration of pembrolizumab</time_frame>
    <description>according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local evaluation of pathological complete response rate</measure>
    <time_frame>Following completion of neoadjuvant systemic treatment, an average of 24 weeks</time_frame>
    <description>defined as absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of NAST (i.e., ypT0/is, ypN0 in the current AJCC staging system)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive disease-free survival (IDFS)</measure>
    <time_frame>3 years</time_frame>
    <description>time from surgery to the first documented occurrence of an event, defined as: Ipsilateral invasive breast tumor recurrence, Ipsilateral local-regional invasive breast cancer recurrence, Distant recurrence, Contralateral invasive breast cancer, Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive disease-free survival (IDFS)</measure>
    <time_frame>5 years</time_frame>
    <description>time from surgery to the first documented occurrence of an event, defined as: Ipsilateral invasive breast tumor recurrence, Ipsilateral local-regional invasive breast cancer recurrence, Distant recurrence, Contralateral invasive breast cancer, Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>3 years</time_frame>
    <description>time from randomization to disease progression, disease recurrence (local, regional, distant, or contralateral [invasive or non invasive]), or death from any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>5 years</time_frame>
    <description>time from randomization to disease progression, disease recurrence (local, regional, distant, or contralateral [invasive or non invasive]), or death from any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>time from randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>time from randomization to death from any cause</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of PD-L1 expression in pre, per and post-treatment tissue</measure>
    <time_frame>Following completion of neoadjuvant systemic treatment, an average of 24 weeks</time_frame>
    <description>by IHC and mass spectrometry-based proteomics; and in plasma samples using quantitative proteomics,</description>
  </other_outcome>
  <other_outcome>
    <measure>Measurement of baseline Circulating tumor cells for prospective validation of their prognostic value in IBC</measure>
    <time_frame>Following completion of neoadjuvant systemic treatment, an average of 24 weeks</time_frame>
    <description>Measurement of baseline CTC for prospective validation of their prognostic value in IBC</description>
  </other_outcome>
  <other_outcome>
    <measure>Disease monitoring</measure>
    <time_frame>Following completion of neoadjuvant systemic treatment, an average of 24 weeks</time_frame>
    <description>Purification of ctDNA and specific sequencing for disease monitoring.</description>
  </other_outcome>
  <other_outcome>
    <measure>Identification of mechanisms of treatment resistance</measure>
    <time_frame>Following completion of neoadjuvant systemic treatment, an average of 24 weeks</time_frame>
    <description>Immune profiling, NGS and mouse xenografing for ex-vivo phenotypic approaches on post-treatment residual disease in order to identify mechanisms of resistance.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Inflammatory Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EC Paclitaxel + Pembrolizumab Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard neoadjuvant chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EC Paclitaxel alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab Injection</intervention_name>
    <description>Patients will receive intravenously 1 dose of Pembrolizumab every 3 weeks</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <other_name>MK3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neoadjuvant EC-paclitaxel chemotherapy</intervention_name>
    <description>The cytotoxic regimen is a combination of dose-dense EC, followed by weekly paclitaxel</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_label>Standard neoadjuvant chemotherapy</arm_group_label>
    <other_name>Epirubicine, Cyclophosphamide, Paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male/female participants who are at least 18 years of age on the day of signing
             informed consent

          2. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
             Evaluation of ECOG is to be performed within 7 days prior to the date of
             randomization. Note: may consider ECOG PS 2 if good rationale provided and discussed
             with Sponsor team.

          3. Able to comply with the protocol,

          4. Patient affiliated to the national &quot;Social Security&quot; regimen or beneficiary of this
             regimen, or any other regimen of social security

          5. Patient (or legally acceptable representative if applicable) has provided written
             informed consent for the trial,

          6. Previously untreated, histologically confirmed diagnosis of breast cancer and
             confirmed inflammatory breast cancer defined as follows:

             - T4d any N following American Joint Committee on Cancer (AJCC)-8th version
             classification: breast erythema, edema and/or peau d'orange, occupying at least 1/3 of
             the breast, with or without underlying palpable mass, duration of history of no more
             than 6 months.

          7. HER2 negative tumors by immunohistochemistry (IHC 0 or 1+) or fluorescent/chromogenic
             in situ hybridization (FISH- or CISH-)

          8. Hormone receptors status known,

          9. No metastases,

         10. Have adequate organ function. Specimens must be collected within 10 days prior to the
             start of study treatment.

         11. Adequate hematologic function: absolute neutrophil count ≥ 1.5 x 109/L AND platelets ≥
             100 x 109 AND Hb ≥ 9.0 g/dL or ≥5.6 mmol/L, Criteria must be met without
             erythropoietin dependency and without packed red blood cell (pRBC) transfusion within
             last 2 weeks.

         12. Adequate liver function: total bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for
             participants with total bilirubin levels &gt;1.5 × ULN AND - ASAT ≤ 2.5 ULN AND ALAT ≤
             2.5 ULN,

         13. Adequate kidney function: serum creatinine ≤ 1.5 ULN or creatinine clearance ≥ 30
             mL/min for participant with creatinine levels &gt;1.5 × institutional ULN, Creatinine
             clearance (CrCl) should be calculated per institutional standard.

         14. International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 ULN unless subject
             is receiving anticoagulant therapy, as long as PT or TCA is within therapeutic range
             of intended use of the anticoagulants,

         15. Adequate cardiac function: left ventricular ejection fraction (LVEF) ≥ 50% (isotopic
             or ultrasound methods),

         16. A female participant is eligible to participate if she is not pregnant (see Appendix
             3), not breastfeeding, and at least one of the following conditions applies:

               1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR

               2. A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the
                  treatment period and for at least 12 months after the last dose of
                  cyclophosphamide and 4 months after the last dose of pembrolizumab, whichever
                  come last.

             Note: Abstinence is acceptable if this is the established and preferred contraception
             for the subject

         17. A male participant must agree to use a contraception as detailed in Appendix 3 of this
             protocol during the treatment period and for at least 6 months after the last dose of
             study treatment and refrain from donating sperm during this period (corresponding to
             time needed to eliminate any study treatments plus an additional 120 days (a
             spermatogenesis cycle) for study treatments with risk of genotoxicity at any dose).

        Exclusion Criteria:

          1. Has metastatic breast cancer,

          2. Has HER2-positive breast cancer,

          3. Has bilateral breast cancer

          4. Prior allogeneic stem cell or solid organ transplantation

          5. A WOCBP who has a positive serum pregnancy test within 72 hours prior to
             randomiza-tion

          6. Is currently participating in or has participated in a study of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             study treatment, Note: Participants who have entered the follow-up phase of an
             investigational study may participate as long as it has been 4 weeks after the last
             dose of the previous investigational agent.

          7. Has known active CNS disease or carcinomatous meningitis.

          8. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in
             dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days prior to the first dose of study drug,

          9. Has a known history of active TB (Bacillus Tuberculosis),

         10. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients,

         11. If subject received major surgery, they must have recovered adequately from the
             toxicity and/or complications from the intervention prior to starting therapy,

         12. Has a known additional malignancy that is progressing or has required active treatment
             within the past 3 years. Note: Participants with basal cell carcinoma of the skin,
             squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma,
             cervical cancer in situ) that have undergone potentially curative therapy are not
             excluded.

         13. Has active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
             drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment,

         14. Has a history of (non-infectious) pneumonitis that required steroids or has current
             pneumonitis,

         15. Has an active infection requiring systemic therapy.

         16. Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator,

         17. Has known psychiatric or substance abuse disorders that would interfere with
             coopera-tion with the requirements of the trial,

         18. Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the screening visit through 120 days
             after the last dose of trial treatment,

         19. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with
             an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,
             CTLA-4, OX 40, CD137).,

         20. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies),

         21. Has known history of Hepatitis B (e.g., HBsAg reactive) or known active Hepatitis C
             virus infection (e.g., HCV RNA [qualitative] is detected)

         22. Has received a live vaccine within 30 days prior to the first dose of study drug.
             Examples of live vaccines include, but are not limited to, the following: measles,
             mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus
             Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection
             are generally killed virus vaccines and are allowed; however, intranasal influenza
             vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Goncalves, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique GENRE, MD</last_name>
    <phone>33 4 91 22 37 78</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margot Berline</last_name>
    <phone>33 4 91 22 37 78</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sint-Augustinus Hospital</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luc Dirix</last_name>
    </contact>
    <investigator>
      <last_name>Dirix</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ahmad Awada, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Ahmad Awada, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Luc Canon</last_name>
    </contact>
    <investigator>
      <last_name>Canon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gand</name>
      <address>
        <city>Gand</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hannelore Denys</last_name>
    </contact>
    <investigator>
      <last_name>Denys</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL</name>
      <address>
        <city>Louvain</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François Duhoux</last_name>
    </contact>
    <investigator>
      <last_name>Duhoux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Pare</name>
      <address>
        <city>Mons</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephane Holbrechts</last_name>
    </contact>
    <investigator>
      <last_name>Holbrechts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Elisabeth</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Vuysteke</last_name>
    </contact>
    <investigator>
      <last_name>Vuysteke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de L'Europe</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GOZY</last_name>
    </contact>
    <investigator>
      <last_name>GOZY, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien GRENIER, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Julien GRENIER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut BERGONIE</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille CHAKIBA-BRUGERE, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Camille CHAKIBA-BRUGERE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CENTRE Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle LEVY, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Christelle LEVY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas BACHELOT, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Thomas BACHELOT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence LEREBOURS, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Florence Lerebours, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne LEHEURTEUR, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Marianne LEHEURTEUR, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie hopital rene huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Lerebours, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Florence Lerebours</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de la loire</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Philippe JACQUIN, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Philippe JACQUIN, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry PETIT, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Thierry PETIT, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT-Oncopole Institut Claudius Rigaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence DALENC, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Florence DALENC, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://institutpaolicalmettes.fr</url>
    <description>Official Website of the sponsor</description>
  </link>
  <reference>
    <citation>Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645.</citation>
    <PMID>28564564</PMID>
  </reference>
  <reference>
    <citation>Binder-Foucard F, Rasamimanana Cerf N, Belot A, Bossard N. Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012. Étude à partir des registres des cancers du réseau Francim. Partie 1 - Tumeurs solides-Synthèse. In: http://www.invs.sante.fr. 2013.</citation>
  </reference>
  <reference>
    <citation>Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer. 1998 Jun 15;82(12):2366-72.</citation>
    <PMID>9635529</PMID>
  </reference>
  <reference>
    <citation>Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011 Mar;22(3):515-523. doi: 10.1093/annonc/mdq345. Epub 2010 Jul 5.</citation>
    <PMID>20603440</PMID>
  </reference>
  <reference>
    <citation>Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007 Oct 1;110(7):1436-44.</citation>
    <PMID>17694554</PMID>
  </reference>
  <reference>
    <citation>McCarthy NJ, Yang X, Linnoila IR, Merino MJ, Hewitt SM, Parr AL, Paik S, Steinberg SM, Hartmann DP, Mourali N, Levine PH, Swain SM. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res. 2002 Dec;8(12):3857-62.</citation>
    <PMID>12473600</PMID>
  </reference>
  <reference>
    <citation>Lerebours F, Bieche I, Lidereau R. Update on inflammatory breast cancer. Breast Cancer Res. 2005;7(2):52-8. Epub 2005 Jan 20. Review.</citation>
    <PMID>15743511</PMID>
  </reference>
  <reference>
    <citation>Chevallier B, Bastit P, Graic Y, Menard JF, Dauce JP, Julien JP, Clavier B, Kunlin A, D'Anjou J. The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients. Br J Cancer. 1993 Mar;67(3):594-601.</citation>
    <PMID>8439510</PMID>
  </reference>
  <reference>
    <citation>Rouëssé J, Friedman S, Sarrazin D, Mouriesse H, Le Chevalier T, Arriagada R, Spielmann M, Papacharalambous A, May-Levin F. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol. 1986 Dec;4(12):1765-71.</citation>
    <PMID>3783202</PMID>
  </reference>
  <reference>
    <citation>Brun B, Otmezguine Y, Feuilhade F, Julien M, Lebourgeois JP, Calitchi E, Roucayrol AM, Ganem G, Huart J, Pierquin B. Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation. Cancer. 1988 Mar 15;61(6):1096-103.</citation>
    <PMID>3342369</PMID>
  </reference>
  <reference>
    <citation>Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol. 1992 Jun;10(6):1014-24. Review.</citation>
    <PMID>1588366</PMID>
  </reference>
  <reference>
    <citation>Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001 Oct 1;92(7):1775-82.</citation>
    <PMID>11745249</PMID>
  </reference>
  <reference>
    <citation>Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, Kau SW, Frye DK, Hortobagyi GN. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2004 Feb;4(6):415-9.</citation>
    <PMID>15023242</PMID>
  </reference>
  <reference>
    <citation>de Matteis A, Nuzzo F, D'Aiuto G, Labonia V, Landi G, Rossi E, Mastro AA, Botti G, De Maio E, Perrone F. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study. Cancer. 2002 Feb 15;94(4):895-901.</citation>
    <PMID>11920456</PMID>
  </reference>
  <reference>
    <citation>Gradishar WJ, Wedam SB, Jahanzeb M, Erban J, Limentani SA, Tsai KT, Olsen SR, Swain SM. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol. 2005 Aug;16(8):1297-304. Epub 2005 May 19.</citation>
    <PMID>15905305</PMID>
  </reference>
  <reference>
    <citation>Espinosa E, Morales S, Borrega P, Casas A, Madroñal C, Machengs I, Illarramendi JA, Lizón J, Moreno JA, Belón J, Janáriz J, de la Puente M, Checa T, Mel JR, González Barón M. Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Chemother Pharmacol. 2004 Dec;54(6):546-52. Epub 2004 Aug 17.</citation>
    <PMID>15316749</PMID>
  </reference>
  <reference>
    <citation>Reitsamer R, Peintinger F, Prokop E, Hitzl W. Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anticancer Drugs. 2005 Sep;16(8):867-70. Erratum in: Anticancer Drugs. 2006 Mar;17(3):363.</citation>
    <PMID>16096435</PMID>
  </reference>
  <reference>
    <citation>Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002 Mar 15;20(6):1456-66.</citation>
    <PMID>11896092</PMID>
  </reference>
  <reference>
    <citation>Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N; National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003 Nov 15;21(22):4165-74. Epub 2003 Oct 14.</citation>
    <PMID>14559892</PMID>
  </reference>
  <reference>
    <citation>Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008 Feb 10;26(5):778-85. doi: 10.1200/JCO.2007.15.0235. Erratum in: J Clin Oncol. 2008 Jun 1;26(16):2793.</citation>
    <PMID>18258986</PMID>
  </reference>
  <reference>
    <citation>Gonçalves A, Pierga JY, Ferrero JM, Mouret-Reynier MA, Bachelot T, Delva R, Fabbro M, Lerebours F, Lotz JP, Linassier C, Dohollou N, Eymard JC, Leduc B, Lemonnier J, Martin AL, Boher JM, Viens P, Roché H. UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. Ann Oncol. 2015 Aug;26(8):1692-7. doi: 10.1093/annonc/mdv216. Epub 2015 May 5.</citation>
    <PMID>25943350</PMID>
  </reference>
  <reference>
    <citation>Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-MacGregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol. 2014 Feb;25(2):384-91. doi: 10.1093/annonc/mdt525. Epub 2013 Dec 18.</citation>
    <PMID>24351399</PMID>
  </reference>
  <reference>
    <citation>Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010 Jan 30;375(9712):377-84. doi: 10.1016/S0140-6736(09)61964-4.</citation>
    <PMID>20113825</PMID>
  </reference>
  <reference>
    <citation>Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6.</citation>
    <PMID>22153890</PMID>
  </reference>
  <reference>
    <citation>Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012 Feb 18;379(9816):633-40. doi: 10.1016/S0140-6736(11)61847-3. Epub 2012 Jan 17. Erratum in: Lancet. 2012 Feb 18;379(9816):616. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.</citation>
    <PMID>22257673</PMID>
  </reference>
  <reference>
    <citation>Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, Charafe-Jauffret E, Pavlyuk M, Kraemer S, Bidard FC, Viens P. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol. 2012 Apr;13(4):375-84. doi: 10.1016/S1470-2045(12)70049-9. Epub 2012 Feb 28.</citation>
    <PMID>22377126</PMID>
  </reference>
  <reference>
    <citation>Disis ML. Immune regulation of cancer. J Clin Oncol. 2010 Oct 10;28(29):4531-8. doi: 10.1200/JCO.2009.27.2146. Epub 2010 Jun 1.</citation>
    <PMID>20516428</PMID>
  </reference>
  <reference>
    <citation>Mei Z, Liu Y, Liu C, Cui A, Liang Z, Wang G, Peng H, Cui L, Li C. Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer. 2014 Mar 18;110(6):1595-605. doi: 10.1038/bjc.2014.46. Epub 2014 Feb 6. Review.</citation>
    <PMID>24504370</PMID>
  </reference>
  <reference>
    <citation>Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S; International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015 Feb;26(2):259-71. doi: 10.1093/annonc/mdu450. Epub 2014 Sep 11.</citation>
    <PMID>25214542</PMID>
  </reference>
  <reference>
    <citation>Schatton T, Scolyer RA, Thompson JF, Mihm MC Jr. Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. Methods Mol Biol. 2014;1102:287-324. doi: 10.1007/978-1-62703-727-3_16. Review.</citation>
    <PMID>24258985</PMID>
  </reference>
  <reference>
    <citation>Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011 Jun 28;105(1):93-103. doi: 10.1038/bjc.2011.189. Epub 2011 May 31. Review.</citation>
    <PMID>21629244</PMID>
  </reference>
  <reference>
    <citation>Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009 Aug 20;114(8):1537-44. doi: 10.1182/blood-2008-12-195792. Epub 2009 May 7.</citation>
    <PMID>19423728</PMID>
  </reference>
  <reference>
    <citation>Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002 Aug;8(8):793-800. Epub 2002 Jun 24. Erratum in: Nat Med 2002 Sep;8(9):1039.</citation>
    <PMID>12091876</PMID>
  </reference>
  <reference>
    <citation>Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009 Dec 21;206(13):3015-29. doi: 10.1084/jem.20090847. Epub 2009 Dec 14.</citation>
    <PMID>20008522</PMID>
  </reference>
  <reference>
    <citation>Hamel KM, Cao Y, Wang Y, Rodeghero R, Kobezda T, Chen L, Finnegan A. B7-H1 expression on non-B and non-T cells promotes distinct effects on T- and B-cell responses in autoimmune arthritis. Eur J Immunol. 2010 Nov;40(11):3117-27. doi: 10.1002/eji.201040690. Epub 2010 Oct 27.</citation>
    <PMID>21061440</PMID>
  </reference>
  <reference>
    <citation>Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008 Jun;8(6):467-77. doi: 10.1038/nri2326. Review.</citation>
    <PMID>18500231</PMID>
  </reference>
  <reference>
    <citation>Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7. Epub 2002 Sep 6.</citation>
    <PMID>12218188</PMID>
  </reference>
  <reference>
    <citation>Reiss KA, Forde PM, Brahmer JR. Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. Immunotherapy. 2014;6(4):459-75. doi: 10.2217/imt.14.9. Review.</citation>
    <PMID>24815784</PMID>
  </reference>
  <reference>
    <citation>Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010 Jan 1;28(1):105-13. doi: 10.1200/JCO.2009.23.7370. Epub 2009 Nov 16. Erratum in: J Clin Oncol. 2010 Feb 1;28(4):708.</citation>
    <PMID>19917869</PMID>
  </reference>
  <reference>
    <citation>Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014 Aug;25(8):1544-50. doi: 10.1093/annonc/mdu112. Epub 2014 Mar 7.</citation>
    <PMID>24608200</PMID>
  </reference>
  <reference>
    <citation>Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, Earl HM, Poole CJ, Hiller L, Dunn JA, Bowden SJ, Twelves C, Bartlett JM, Mahmoud SM, Rakha E, Ellis IO, Liu S, Gao D, Nielsen TO, Pharoah PD, Caldas C. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014 Aug;25(8):1536-43. doi: 10.1093/annonc/mdu191. Epub 2014 Jun 9.</citation>
    <PMID>24915873</PMID>
  </reference>
  <reference>
    <citation>Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 2009;11(2):R15. doi: 10.1186/bcr2234. Epub 2009 Mar 9.</citation>
    <PMID>19272155</PMID>
  </reference>
  <reference>
    <citation>Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 2007;8(8):R157.</citation>
    <PMID>17683518</PMID>
  </reference>
  <reference>
    <citation>Sabatier R, Finetti P, Mamessier E, Raynaud S, Cervera N, Lambaudie E, Jacquemier J, Viens P, Birnbaum D, Bertucci F. Kinome expression profiling and prognosis of basal breast cancers. Mol Cancer. 2011 Jul 21;10:86. doi: 10.1186/1476-4598-10-86.</citation>
    <PMID>21777462</PMID>
  </reference>
  <reference>
    <citation>Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni B, Mamessier E, Tallet A, Chabannon C, Extra JM, Jacquemier J, Viens P, Birnbaum D, Bertucci F. A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat. 2011 Apr;126(2):407-20. doi: 10.1007/s10549-010-0897-9. Epub 2010 May 21.</citation>
    <PMID>20490655</PMID>
  </reference>
  <reference>
    <citation>Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC, Muggia F, Symmans WF. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res. 2001 Oct;7(10):3025-30.</citation>
    <PMID>11595690</PMID>
  </reference>
  <reference>
    <citation>Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rébé C, Coudert B, Martin F, Bizollon MH, Vanoli A, Coutant C, Fumoleau P, Bonnetain F, Ghiringhelli F. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol. 2011 Jul;224(3):389-400. doi: 10.1002/path.2866. Epub 2011 Mar 25.</citation>
    <PMID>21437909</PMID>
  </reference>
  <reference>
    <citation>Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Bin Amer S, Tulbah A, Ajarim D, Al-Tweigeri T, Dermime S. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006 Mar;8(3):190-8.</citation>
    <PMID>16611412</PMID>
  </reference>
  <reference>
    <citation>Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer SM, Al-Tweigeri T, Dermime S. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer. 2007 Aug 15;121(4):751-8.</citation>
    <PMID>17415709</PMID>
  </reference>
  <reference>
    <citation>Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer. 2008 Feb 23;8:57. doi: 10.1186/1471-2407-8-57.</citation>
    <PMID>18294387</PMID>
  </reference>
  <reference>
    <citation>Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014 May 15;20(10):2773-82. doi: 10.1158/1078-0432.CCR-13-2702. Epub 2014 Mar 19.</citation>
    <PMID>24647569</PMID>
  </reference>
  <reference>
    <citation>Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One. 2014 Feb 14;9(2):e88557. doi: 10.1371/journal.pone.0088557. eCollection 2014.</citation>
    <PMID>24551119</PMID>
  </reference>
  <reference>
    <citation>Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014 Apr;2(4):361-70. doi: 10.1158/2326-6066.CIR-13-0127. Epub 2014 Jan 10.</citation>
    <PMID>24764583</PMID>
  </reference>
  <reference>
    <citation>Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D, Bertucci F. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015 Mar 10;6(7):5449-64.</citation>
    <PMID>25669979</PMID>
  </reference>
  <reference>
    <citation>Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, Bossuyt V, Pusztai L, Lannin DR, Rimm DL. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res. 2015 Apr;3(4):326-32. doi: 10.1158/2326-6066.CIR-14-0133. Epub 2014 Dec 19.</citation>
    <PMID>25527356</PMID>
  </reference>
  <reference>
    <citation>Bertucci F, Finetti P, Colpaert C, Mamessier E, Parizel M, Dirix L, Viens P, Birnbaum D, van Laere S. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget. 2015 May 30;6(15):13506-19.</citation>
    <PMID>25940795</PMID>
  </reference>
  <reference>
    <citation>Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, Tamada K, Chen L. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005 Feb 1;65(3):1089-96.</citation>
    <PMID>15705911</PMID>
  </reference>
  <reference>
    <citation>Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004 Feb 1;64(3):1140-5.</citation>
    <PMID>14871849</PMID>
  </reference>
  <reference>
    <citation>Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol. 2010 Oct;37(5):430-9. doi: 10.1053/j.seminoncol.2010.09.005. Review.</citation>
    <PMID>21074057</PMID>
  </reference>
  <reference>
    <citation>Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, Salomao D, Cheville J, Hirano F, Lin W, Kasperbauer JL, Ballman KV, Chen L. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003 Oct 1;63(19):6501-5.</citation>
    <PMID>14559843</PMID>
  </reference>
  <reference>
    <citation>Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer. 2014 Feb 18;2:3. doi: 10.1186/2051-1426-2-3. eCollection 2014.</citation>
    <PMID>24829760</PMID>
  </reference>
  <reference>
    <citation>Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005 Apr 1;23(10):2346-57.</citation>
    <PMID>15800326</PMID>
  </reference>
  <reference>
    <citation>Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515-48. Review.</citation>
    <PMID>15771580</PMID>
  </reference>
  <reference>
    <citation>Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13866-71. Epub 2001 Nov 6.</citation>
    <PMID>11698646</PMID>
  </reference>
  <reference>
    <citation>Zhang X, Schwartz JC, Guo X, Bhatia S, Cao E, Lorenz M, Cammer M, Chen L, Zhang ZY, Edidin MA, Nathenson SG, Almo SC. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity. 2004 Mar;20(3):337-47. Erratum in: Immunity. 2004 May;20(5):651.</citation>
    <PMID>15030777</PMID>
  </reference>
  <reference>
    <citation>Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004 Jul 15;173(2):945-54.</citation>
    <PMID>15240681</PMID>
  </reference>
  <reference>
    <citation>Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, Wooters J, Qiu Y, Jussif JM, Carter LL, Wood CR, Chaudhary D. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 2004 Sep 10;574(1-3):37-41.</citation>
    <PMID>15358536</PMID>
  </reference>
  <reference>
    <citation>Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009 May;229(1):114-25. doi: 10.1111/j.1600-065X.2009.00767.x. Review.</citation>
    <PMID>19426218</PMID>
  </reference>
  <reference>
    <citation>Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005 Nov;25(21):9543-53.</citation>
    <PMID>16227604</PMID>
  </reference>
  <reference>
    <citation>Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010 Jul;236:219-42. doi: 10.1111/j.1600-065X.2010.00923.x. Review.</citation>
    <PMID>20636820</PMID>
  </reference>
  <reference>
    <citation>Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Review. Erratum in: Lancet Oncol. 2019 May;20(5):e242.</citation>
    <PMID>28271869</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>May 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2018</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Inflammatory Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

